Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full-body radiation protection systems for interventional medicine practitioners, has announced the positive results of the NOVARAD clinical study. This study, the first ever in the world to evaluate exposure to X-rays in interventional neuroradiology, aimed at assessing the effectiveness of Nova-X in protecting from head to toe the whole staff team in cath labs from exposure to X-rays during interventional procedures.